Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis.

ABSTRACT: Prior pooled analysis of eribulin studies (301 and 305) indicated eribulin prolonged overall survival (OS) in patients with locally advanced/metastatic breast cancer (MBC) regardless of visceral or nonvisceral disease. This hypothesis-generating post hoc analysis examined the efficacy of eribulin according to the location of metastatic sites at baseline in 1864 pretreated patients with locally advanced/MBC from studies 301 and 305. Analyses included OS, progression-free survival (PFS), and objective response rate; OS and PFS were also analyzed according to estrogen-receptor status. Eribulin appeared efficacious in patients with locally advanced/MBC, irrespective of the location of metastases at baseline. A nominally significant difference in OS in favor of patients randomized to eribulin c

SUBMITTER: O'Shaughnessy J 

PROVIDER: S-EPMC7343788 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature